Clinical trials: Renal Cancer
Renal Cell Carcinoma
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.
- Trial name
- NCT01354431
- Testing
- nivolumab
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 168 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Bladder Cancer, Cervical Cancer
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00666978
- Testing
- smoking cessation intervention, bupropion hydrochloride, gene expression analysis
- Where
- 2 sites in United States
- Volunteers
- 540 people
- Sponsor
- Lisa Sanderson Cox, PhD
Renal Cell Carcinoma
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa.
- Trial name
- INTORACT (NCT00631371)
- Testing
- Bevacizumab, Temsirolimus, Interferon-Alfa 9MU
- Where
- 172 sites in United States, Argentina and 28 more
- Volunteers
- 791 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following…
- Trial name
- IMmotion010 (NCT03024996)
- Testing
- Atezolizumab
- Where
- 186 sites in United States, Argentina and 26 more
- Volunteers
- 778 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Myelodysplastic Syndrome
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
This is a pilot study which will be done in a small number of patients. The purpose of this study is to test the safety and benefit of giving a type of chemotherapy - cyclophosphamide - after the transplant to prevent graft…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT02360111
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib…
- Trial name
- CANTATA (NCT03428217)
- Testing
- CB-839, Cabozantinib
- Where
- 133 sites in United States, Australia and 6 more
- Volunteers
- 444 people
- Sponsor
- Calithera Biosciences, Inc
Renal Cell Carcinoma
Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma
About 27,000 new cases of renal cell carcinoma (RCC) are diagnosed every year in the United States. 11,000 of these cases will die from the disease.
- Trial name
- NCT00001703
- Testing
- incomplete Freund's adjuvant, von Hippel-Lindau peptide vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
CT-011 is an investigational monoclonal antibody. Monoclonal antibodies are a type of drug that are known to target specific cells (in this case, cells in the immune system) The DC RCC Vaccine is agent that tries to help the…
- Trial name
- NCT01441765
- Testing
- CT-011, DC/RCC fusion vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Beth Israel Deaconess Medical Center
Advanced Cancer
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
- Trial name
- FRACTION-RCC (NCT02996110)
- Testing
- Nivolumab, Ipilimumab, Relatlimab
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 182 people
- Sponsor
- Bristol-Myers Squibb
Kidney Transplantation
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
The aim of the study is to evaluate the efficacy of new immunosuppressive protocol based on two applications of anti-CD52 MabCampath (Alemtuzumab) a single dose of anti-TNF-α Remicade (infliximab) monoclonal antibodies in the…
- Trial name
- NCT02711202
- Testing
- MabCampath,, Remicade, Sirolimus
- Volunteers
- 20 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Carcinoma, Renal Cell
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
This is for subjects with metastatic Renal Cell Cancer (RCC). There are four Food and Drug Administration (FDA) approved drugs for first-line therapy of Renal Cell Cancer (RCC) and two for second-line therapy.
- Trial name
- NCT02560012
- Testing
- Sunitinib, Temsirolimus, Sorafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- The University of Texas Health Science Center, Houston
Bladder Cancer, Prostate Cancer
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures.
- Conditions
- Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor
- Trial name
- NCT05696444
- Testing
- RAS Prostatectomy, RAS Cystectomy, RAS Nephrectomy
- Where
- 6 sites in United States
- Volunteers
- 144 people
- Sponsor
- Medtronic - MITG
Cutaneous Leiomyomas, Hereditary Leiomyomatosis and Renal Cell Cancer
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Cutaneous leiomyomas are benign tumors of smooth muscle origin. They can be very painful, and current treatments for the tumors and for the associated pain do not produce satisfactory results.
- Trial name
- NCT00971620
- Testing
- Botulinum toxin type A
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Kidney Cancer
Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging
The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with suspected kidney cancer with the same accuracy as conventional ultrasound and…
- Trial name
- NCT04021238
- Testing
- Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Renal Cell Carcinoma
Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
This investigator driven study will examine the safety, efficacy and biological effects of combining pembrolizumab (MK-3475) an antibody targeted against anti-programmed cell death 1 (PD-1), with stereotactic ablative body…
- Trial name
- RAPPORT (NCT02855203)
- Testing
- Stereotactic Ablative Body Radiosurgery (SABR), Pembrolizumab
- Where
- 2 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Renal Cell Carcinoma
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC).
- Trial name
- NCT02853344
- Testing
- Pembrolizumab
- Volunteers
- 275 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancers
Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients
This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for patients with advanced colorectal cancer that no longer responds to standard therapies.
- Trial name
- NCT02046174
- Testing
- RENCA macrobeads
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- The Rogosin Institute